Skip to Content

ImmunoCellular Therapeutics Ltd IMUC

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

ImmunoCellular Therapeutics Ltd is a US-based clinical-stage biotechnology company. It is engaged in developing immune-based therapies for the treatment of cancers which can elicit an immune response against several antigens. The company has developed ICT-107, which is a dendritic cell (DC) immunotherapy for the treatment of newly diagnosed glioblastoma multiforme (GBM), which is a lethal type of brain cancer. It develops Immunotherapies for treating cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.

Contact
30721 Russell Ranch Road, Suite 140
Westlake Village, CA, 91362
T +1 818 264-2300
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2018
Fiscal Year End Dec 31, 2018
Stock Type
Employees 4